Giulia Ferrannini

About me
Publications
CV
Public outreach and news

About me

Ongoing: Postodoctoral Researcher, Cardiology Unit, Heart Failure group, Karolinska Institutet
and Consultant in Internal Medicine, Södertälje hospital
2020 - 2023: PhD student at Karolinska Institutet, Stockholm, Sweden
2014 - 2019: Specialisation in Internal Medicine - University of Torino,
Italy
2014 Research Fellow at Naomi Berrie Diabetes Center, Columbia University,
New York, NY, USA
2007 - 2013: Medical school - University of Modena and Reggio Emilia, Italy

Articles

Article: JOURNAL OF CLINICAL PERIODONTOLOGY. 2025;52(1):16-23
Does Periodontitis Increase the Risk for Future Cardiovascular Events? Long-Term Follow-Up of the PAROKRANK Study
Norhammar A; Naesman P; Buhlin K; de Faire U; Ferrannini G; Gustafsson A; Kjellstrom B; Kvist T; Jaghagen EL; Lindahl B; Nygren A; Naslund U; Svenungsson E; Klinge B; Ryden L
Article: JCI INSIGHT. 2024;9(24):e180637
Fasting substrates predict chronic kidney disease progression in CREDENCE trial patients with type 2 diabetes
Ferrannini E; Baldi S; Scozzaro MT; Ferrannini G; Hansen MK
Article: LANCET DIABETES & ENDOCRINOLOGY. 2024;12(11):790-798
Dysglycaemia screening and its prognostic impact in patients with coronary artery disease: experiences from the EUROASPIRE IV and V cohort studies
Ferrannini G; Tuomilehto J; De Backer G; Kotseva K; Mellbin L; Schnell O; Wood D; De Bacquer D; Ryden L
Article: EUROPEAN JOURNAL OF HEART FAILURE. 2024
Characterizing atrial fibrillation in patients with and without heart failure across the ejection fraction spectrum: Incidence, prevalence, and treatment strategies
Valente V; Ferrannini G; Benson L; Gatti P; Guidetti F; Melin M; Braunschweig F; Linde C; Dahlstrom U; Lund LH; Fudim M; Savarese G
Article: EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY. 2024;10(4):296-306
Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes: data from the Swedish Heart Failure and Swedish National Diabetes Registries
Wallner M; Biber ME; Stolfo D; Sinagra G; Benson L; Dahlstrom U; Gudbjornsdottir S; Cosentino F; Mol PGM; Rosano GMC; Butler J; Metra M; Lund LH; Ferrannini G; Savarese G
Article: ESC HEART FAILURE. 2024;11(2):759-771
N-terminal pro-B-type natriuretic peptide concentrations, testing and associations with worsening heart failure events
Ferrannini G; Benson L; Lautsch D; Dahlstroem U; Lund LH; Savarese G; Carrero JJ
Article: BMJ OPEN. 2024;14(3):e078983
Universal screening for early detection of chronic autoimmune, metabolic and cardiovascular diseases in the general population using capillary blood (UNISCREEN): low-risk interventional, single-centre, pilot study protocol
Merolla A; De Lorenzo R; Ferrannini G; Renzi C; Ulivi F; Bazzigaluppi E; Lampasona V; Bosi E
Article: DIABETES CARE. 2024;66(SUPPL 1):S493
High mannose correlates with surrogate indexes of insulin resistance and predicts cardiovascular events independently of glycaemic status and traditional risk factors
Fortin E; Campi B; Ferrannini E; Mari A; Mellbin L; Norhammar A; Nasman P; Ryden L; Saba A; Ferrannini G
Article: CARDIOVASCULAR DIABETOLOGY. 2024;23(1):25
Sex differences in the association between insulin resistance and non-fatal myocardial infarction across glycaemic states
Riccio A; Fortin E; Mellbin L; Norhammar A; Naesman P; Ryden L; Sesti G; Ferrannini G
Article: FRONTIERS IN CARDIOVASCULAR MEDICINE. 2024;11:1385281
The management of heart failure in Sweden-the physician's perspective: a survey
Ferrannini G; Biber ME; Abdi S; Stahlberg M; Lund LH; Savarese G
Article: SCANDINAVIAN CARDIOVASCULAR JOURNAL. 2023;57(1):2166101
Gender differences in cardiovascular risk, treatment, and outcomes: a post hoc analysis from the REWIND trial
Ferrannini G; Maldonado JM; Raha S; Rao-Melacini P; Khatun R; Atisso C; Shurzinske L; Gerstein HC; Ryden L; Bethel MA
Journal article: EUROPEAN HEART JOURNAL. 2023;44:ehad655.1443
High mannose correlates with surrogate indexes of insulin resistance and predicts cardiovascular events independently of glycaemic status and traditional risk factors
Fortin E; Campi B; Ferrannini E; Mari A; Mellbin L; Norhammar A; Nasman P; Ryden L; Saba A; Ferrannini G
Journal article: EUROPEAN HEART JOURNAL. 2023;44:ehad655.974
The management of patients with heart failure in Sweden: a survey conducted among physicians in Sweden
Ferrannini G; Biber ME; Abdi S; Stalberg M; Lund LH; Savarese G
Journal article: EUROPEAN HEART JOURNAL. 2023;44:ehad655.2535
Association between body mass index and outcomes in heart failure across the ejection fraction spectrum: data from the Swedish Heart Failure Registry
Ferrannini G; Rodolico D; Amario DD; Dahlstrom U; Lund LH; Savarese G
Article: EUROPEAN JOURNAL OF HEART FAILURE. 2023;25(9):1648-1658
Real-world use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry
Stolfo D; Lund LH; Benson L; Lindberg F; Ferrannini G; Dahlstrom U; Sinagra G; Rosano GMC; Savarese G
Article: CARDIOVASCULAR DIABETOLOGY. 2023;22(1):208
Empagliflozin improves insulin sensitivity in patients with recent acute coronary syndrome and newly detected dysglycaemia Experiences from the randomized, controlled SOCOGAMI trial
Fortin E; Lundin M; Mellbin L; Norhammar A; Naesman P; Smetana S; Soerensson P; Ferrannini E; Ryden L; Ferrannini G
Article: EUROPEAN JOURNAL OF HEART FAILURE. 2023;25(8):1418-1428
Eligibility for vericiguat in a real-world heart failure population according to trial, guideline and label criteria: Data from the Swedish Heart Failure Registry
Nguyen NV; Lindberg F; Benson L; Ferrannini G; Imbalzano E; Mol PGM; Dahlstrom U; Rosano GMC; Ezekowitz J; Butler J; Lund LH; Savarese G
Article: CARDIOVASCULAR DIABETOLOGY. 2023;22(1):100
Extremes of both weight gain and weight loss are associated with increased incidence of heart failure and cardiovascular death: evidence from the CANVAS Program and CREDENCE
Ferrannini G; Pollock C; Natali A; Yavin Y; Mahaffey KW; Ferrannini E
Article: RHEUMATOLOGY. 2023;62(3):1187-1196
Antiphospholipid antibodies in patients with calcific aortic valve stenosis
Plunde O; Svenungsson E; Ferrannini G; Franco-Cereceda A; Back M
Article: SCANDINAVIAN CARDIOVASCULAR JOURNAL. 2022;56(1):337-342
Long-term prognosis after a first myocardial infarction: eight years follow up of the case-control study PAROKRANK
Ferrannini G; Almosawi M; Buhlin K; De Faire U; Kjellstrom B; Klinge B; Nygren A; Nasman P; Svenungsson E; Ryden L; Norhammar A
Article: EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY. 2022;9(1):10-17
Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: a nationwide registry analysis
Ferrannini G; Lund LH; Benson L; Rizzo M; Almahmeed W; Rosano GMC; Savarese G; Cosentino F
Article: DIABETES RESEARCH AND CLINICAL PRACTICE. 2022;193:110141
SOdium-glucose CO-transporter inhibition in patients with newly detected Glucose Abnormalities and a recent Myocardial Infarction (SOCOGAMI)
Lundin M; Ferrannini G; Mellbin L; Johansson I; Norhammar A; Nasman P; Shahim B; Smetana S; Venkateshvaran A; Wang A; Sorensson P; Ryden L
Article: EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING. 2022;21(7):717-723
Gender differences in lifestyle management among coronary patients and the association with education and age: results from the ESC EORP EUROASPIRE V registry
Vynckier P; Ferrannini G; Kotseva K; Gevaert S; De Bacquer D; De Smedt D
Article: CARDIOVASCULAR DIABETOLOGY. 2022;21(1):195
Plasma mannose as a novel marker of myocardial infarction across different glycaemic states: a case control study
Fortin E; Ferrannini G; Campi B; Mellbin L; Norhammar A; Nasman P; Saba A; Ferrannini E; Ryden L
Article: DIABETES CARE. 2022;45(9):2111-2117
Measures of Insulin Resistance as a Screening Tool for Dysglycemia in Patients With Coronary Artery Disease: A Report From the EUROASPIRE V Population
Ferrannini G; De Bacquer D; Erlund I; Gyberg V; Kotseva K; Mellbin L; Norhammar A; Schnell O; Tuomilehto J; Vihervaara T; Wood D; Ryden L
Article: CARDIOVASCULAR DIABETOLOGY. 2022;21(1):129
Mannose-binding lectin does not explain the dismal prognosis after an acute coronary event in dysglycaemic patients. A report from the GAMI cohort
Meziani S; Ferrannini G; Bjerre M; Hansen TK; Ritsinger V; Norhammar A; Gyberg V; Nasman P; Ryden L; Mellbin LG
Article: CARDIOVASCULAR DIABETOLOGY. 2022;21(1):127
Liver function markers predict cardiovascular and renal outcomes in the CANVAS Program
Ferrannini G; Rosenthal N; Hansen MK; Ferrannini E
Article: JOURNAL OF CARDIAC FAILURE. 2022;28(7):1050-1062
Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population
Thorvaldsen T; Ferrannini G; Mellbin L; Benson L; Cosentino F; Mcmurray JJV; Dahlstrom U; Lund LH; Savarese G
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2022;29(2):344-351
Gender gap in risk factor control of coronary patients far from closing: results from the European Society of Cardiology EUROASPIRE V registry
Vynckier P; Ferrannini G; Ryden L; Jankowski P; De Backer T; Gevaert S; De Bacquer D; De Smedt D
Article: DIABETES RESEARCH AND CLINICAL PRACTICE. 2022;183:109156
Saving time by replacing the standardised two-hour oral glucose tolerance test with a one-hour test Validation of a new screening algorithm in patients with coronary artery disease from the ESC-EORP EUROASPIRE V registry
Ferrannini G; De Bacquer D; Gyberg V; De Backer G; Kotseva K; Mellbin LG; Risebrink R; Tuomilehto J; Wood D; Ryden L
Article: INTERNATIONAL JOURNAL OF CARDIOLOGY. 2022;346:86-92
Mannose as a biomarker of coronary artery disease: Angiographic evidence and clinical significance
Ferrannini E; Marx N; Andreini D; Campi B; Saba A; Gorini M; Ferrannini G; Milzi A; Magnoni M; Maseri A; Maggioni AP; Burgmaier M
Journal article: EUROPEAN HEART JOURNAL. 2021;42(Supplement_1):ehab724.1106
Long term outcome after a first myocardial infarction
Almosawi M; Ferrannini G; Buhlin K; Gustafsson A; Kjellstrom B; Klinge B; Nygren Å; Nasman P; Svenungsson E; Ryden L; Norhammar A
Journal article: EUROPEAN HEART JOURNAL. 2021;42(Supplement_1):ehab724.1120
Periodontitis and cardiovascular outcome – a prospective follow-up of the PAROKRANK cohort
Ferrannini G; Norhammar A; Almosawi M; Kjellstrom B; Buhlin K; De Faire U; Gustafsson A; Nygren LA; Nasman P; Lindahl B; Naslund U; Svenungsson E; Klinge B; Ryden L
Article: CARDIOVASCULAR DRUGS AND THERAPY. 2021;35(4):801-808
Medical Treatment in Coronary Patients: Is there Still a Gender Gap? Results from European Society of Cardiology EUROASPIRE V Registry
Vynckier P; Ferrannini G; Ryden L; Tokgozoglu L; Bruthans J; Kotseva K; Wood D; De Backer T; Gevaert S; De Bacquer D; De Smedt D
Article: EUROPEAN HEART JOURNAL. 2021;42(26):2565-2573
Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin
Ferrannini G; Gerstein H; Colhoun HM; Dagenais GR; Diaz R; Dyal L; Lakshmanan M; Mellbin L; Probstfield J; Riddle MC; Shaw JE; Avezum A; Basile JN; Cushman WC; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Pais P; Pirags V; Pogosova N; Raubenheimer PJ; Sheu WH-H; Ryden L
Article: EUROPEAN JOURNAL OF HEART FAILURE. 2021;23(6):1012-1022
Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry
Becher PM; Schrage B; Ferrannini G; Benson L; Butler J; Carrero JJ; Cosentino F; Dahlstrom U; Mellbin L; Rosano GMC; Sinagra G; Stolfo D; Lund LH; Savarese G
Article: DIABETES RESEARCH AND CLINICAL PRACTICE. 2021;175:108796
Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility
Ferrannini G; Savarese G; Ryden L
Article: CARDIOVASCULAR DIABETOLOGY. 2021;20(1):38
Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys
Ferrannini G; De Bacquer D; Vynckier P; De Backer G; Gyberg V; Kotseva K; Mellbin L; Norhammar A; Tuomilehto J; Wood D; Ryden L
Article: FRONTIERS IN CARDIOVASCULAR MEDICINE. 2021;8:790289
Differential Proteomics of Cardiovascular Risk and Coronary Artery Disease in Humans
Ferrannini E; Manca ML; Ferrannini G; Andreotti F; Andreini D; Latini R; Magnoni M; Williams SA; Maseri A; Maggioni AP
Article: DIABETES CARE. 2020;43(9):2001-2009
Is Coronary Artery Disease Inevitable in Type 2 Diabetes? From a Glucocentric to a Holistic View on Patient Management
Ferrannini G; Norhammar A; Gyberg V; Mellbin L; Ryden L
Article: DIABETES CARE. 2020;43(4):726-733
Screening for Glucose Perturbations and Risk Factor Management in Dysglycemic Patients With Coronary Artery Disease-A Persistent Challenge in Need of Substantial Improvement: A Report From ESC EORP EUROASPIRE V
Ferrannini G; De Bacquer D; De Backer G; Kotseva K; Mellbin L; Wood D; Ryden L
Article: DIABETES CARE. 2020;43(4):843-851
Coronary Artery Disease and Type 2 Diabetes: A Proteomic Study
Ferrannini G; Manca ML; Magnoni M; Andreotti F; Andreini D; Latini R; Maseri A; Maggioni AP; Ostroff RM; Williams SA; Ferrannini E
Article: DIABETES & VASCULAR DISEASE RESEARCH. 2020;17(3):1479164120922123-147916412092212
Antiphospholipid antibodies in patients with dysglycaemia: A neglected cardiovascular risk factor?
Ferrannini G; Svenungsson E; Kjellstrom B; Elvin K; Grosso G; Nasman P; Ryden L; Norhammar A
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2019;26(2_SUPPL):81-91
Risk factor reduction in type 2 diabetes demands a multifactorial approach
Ryden L; Ferrannini G; Mellbin L
Article: ENDOCRINE. 2017;55(3):885-898
Pituitary growth hormone (GH) secretion is partially rescued in HIV-infected patients with GH deficiency (GHD) compared to hypopituitary patients
Diazzi C; Brigante G; Ferrannini G; Ansaloni A; Zirilli L; De Santis MC; Zona S; Guaraldi G; Rochira V
Article: MOLECULAR METABOLISM. 2016;5(10):948-958
Genetic backgrounds determine brown remodeling of white fat in rodents
Ferrannini G; Namwanje M; Fang B; Damle M; Li D; Liu Q; Lazar MA; Qiang L
Article: DIABETES CARE. 2015;38(9):1730-1735
Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition
Ferrannini G; Hach T; Crowe S; Sanghvi A; Hall KD; Ferrannini E
Show more

All other publications

Conference publication: EUROPEAN JOURNAL OF HEART FAILURE. 2024;26:128
Etiology of heart failure across the ejection fraction spectrum and association with prognosis
Kozman KK; Ferrannini G; Benson L; Dahlstrom U; Hage C; Savarese G; Shahim B; Lund LH
Conference publication: EUROPEAN JOURNAL OF HEART FAILURE. 2024;26:8-9
Characterizing atrial fibrillation in patients with and without heart failure and across the ejection fraction spectrum: incidence, prevalence, and treatment strategies
Valente V; Ferrannini G; Gatti P; Guidetti F; Benson L; Lund LH; Melin M; Braunschweig F; Dahlstrom U; Fudim M; Savarese G
Conference publication: EUROPEAN JOURNAL OF HEART FAILURE. 2024;26:326-327
Insulin therapy in patients with heart failure and type 2 diabetes: predictors of use and associations with outcomes. Data from the Swedish Heart Failure Registry and National Diabetes Registry
Biber M; Rahimi A; Benson L; Cosentino F; Dahlstrom U; Gudbjornsdottir S; Lund L; Savarese G; Ferrannini G
Conference publication: EUROPEAN JOURNAL OF HEART FAILURE. 2024;26:324-325
Pharmacological treatment patterns and outcomes according to the coexistence of heart failure and type 2 diabetes. Data from the Swedish Heart Failure Registry and National Diabetes Registry
Musella FF; Ferrannini G; Benson L; Dahlstrom U; Gudbjornsdottir S; Cosentino F; Guidetti F; Boccalatte M; Sibilio G; Rosano GMC; Lund LH; Savarese G
Conference publication: EUROPEAN JOURNAL OF HEART FAILURE. 2024;26:369
Weight loss during hospitalization for heart failure while receiving intravenous loop diuretic is associated with lower risk of rehospitalization regardless BMI: data from the SwedeHF registry
Erhardsson M; Lund L; Benson L; Faxen UL; Ferrannini G; Savarese G; Dahlstrom U; Hage C
Conference publication: DIABETOLOGIA. 2024;67:S475-S476
Screening for previously unknown dysglycaemia and its prognostic impact in patients with coronary artery disease; results from the EUROASPIRE programme
Ferrannini G; Tuomilehto J; De Backer G; Kotseva K; Mellbin L; Schnell O; Wood D; De Bacquer D; Ryden L
Conference publication: DIABETOLOGIA. 2024;67:S99-S100
The interaction between type 2 diabetes and chronic kidney disease on heart failure outcomes: observational study from the Swedish Heart Failure and the Swedish National Diabetes Registries
Merolla A; Valente V; Benson L; Dahlstrom U; Lund LH; Gudbjornsdottir S; Cosentino F; Savarese G; Ferrannini G
Editorial comment: EUROPEAN HEART JOURNAL. 2023;44(28):2557-2559
Risk prediction in patients with diabetes: is SCORE 2D the perfect solution?
Ryden L; Ferrannini G; Stand E
Corrigendum: EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY. 2023;9(3):293
Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: A nationwide registry analysis (Vol 9, pg 10, 2023)
Ferrannini G; Lund LH; Benson L; Rizzo M; Almahmeed W; Rosano GMC; Savarese G; Cosentino F
Thesis / dissertation: 2023
Dysglycaemia and cardiovascular disease. Aspects on screening, management, and prognosis
Ferrannini, Giulia
Conference publication: DIABETOLOGIA. 2023;66(SUPPL 1):S247
Sex differences in the association between insulin resistance indexes and myocardial infarction in individuals with different glycaemic states
Riccio A; Mellbin L; Norhammar A; Nasman P; Ryden L; Sesti G; Ferrannini G
Conference publication: EUROPEAN JOURNAL OF HEART FAILURE. 2023;25:21
Extremes of both weight gain and weight loss are associated with increased incidence of heart failure and cardiovascular death: evidence from the CANVAS Program and CREDENCE
Ferrannini GG; Pollock C; Natali A; Yavin Y; Mahaffey KW; Ferrannini E
Conference publication: EUROPEAN JOURNAL OF HEART FAILURE. 2023;25:135-136
N-terminal pro-B-type natriuretic peptide concentrations, testing and associations with outcomes: an analysis of the swedish heart failure registry and the stockholm creatinine measurements cohorts
Ferrannini GG; Savarese G; Benson L; Lautsch D; Dahlstrom U; Lund L; Carrero JJ
Conference publication: DIABETOLOGIA. 2023;66(SUPPL 1):S243-S244
Empagliflozin improves insulin sensitivity in patients with a recent coronary syndrome and newly detected dysglycaemia
Ferrannini G; Fortin E; Mellbin L; Norhammar A; Nasman P; Smetana S; Ferrannini E; Ryden L
Editorial comment: DIABETES CARE. 2022;45(10):e146-e147
Dulaglutide and a Composite Outcome Reflecting Atherosclerosis in the REWIND Trial: A Post Hoc Analysis
Ferrannini G; Mellbin LG; Kirabo F; Ramasundarahettige C; Gerstein HC; Ryden L
Review: HEART FAILURE CLINICS. 2022;18(4):551-559
SGLT2 Inhibitors in Type 2 Diabetes Mellitus
Ferrannini G; Savarese G; Cosentino F
Editorial comment: EUROPEAN CARDIOLOGY. 2022;17:e12
New Trial Evidence on Heart Failure: Highlights from the European Society of Cardiology Congress 2021
Ferrannini G; Savarese G
Conference publication: DIABETOLOGIA. 2022;65(SUPPL 1):S413
Liver function markers predict cardiovascular and renal outcomes in the CANVAS Program
Ferrannini E; Ferrannini G; Rosenthal N; Hansen MK
Conference publication: EUROPEAN HEART JOURNAL. 2022;43:2400
Does dulaglutide impact a composite outcome reflecting atherosclerosis? A post-hoc analysis of the REWIND trial
Ferrannini G; Mellbin L; Kirabo F; Ramasundarahettige C; Herstein HG; Ryden L
Conference publication: DIABETOLOGIA. 2022;65(SUPPL 1):S443
Measures of insulin resistance as a screening tool for dysglycaemia in patients with coronary artery disease: a report from the EUROASPIRE V population
Ferrannini G; De Bacquer D; Erlund I; Gyberg V; Kotseva K; Mellbin L; Norhammar A; Schnell O; Tuomilehto J; Vihervaara T; Wood D; Ryden L
Conference publication: DIABETOLOGIA. 2022;65(SUPPL 1):S412-S413
Plasma mannose and a first myocardial infarction: associations according to glycaemic state
Fortin E; Ferrannini G; Campi B; Mellbin L; Norhammar A; Nasman P; Saba A; Ferrannini E; Ryden L
Editorial comment: LANCET DIABETES & ENDOCRINOLOGY. 2022;10(1):3-5
Is the impact of add on heart failure therapy influenced by background therapy?
Ryden L; Ferrannini G
Editorial comment: EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY. 2021;7(3):e4
SGLT2i: new perspectives in diabetes and kidney disease
Ferrannini G; Cosentino F
Editorial comment: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2021;28(1):18-21
Is cardioprotection with GLP-1 receptor agonists a class effect?
Ryden L; Ferrannini G; Mellbin L
Conference publication: DIABETOLOGIA. 2021;64(SUPPL 1):4-5
Gender differences in cardiovascular risk, treatment, and outcomes: a post-hoc analysis from the REWIND trial
Ferrannini G; Maldonado JM; Raha S; Rao-Melacini P; Khatun R; Atisso C; Shurzinske L; Gerstein H; Ryden L; Bethel MA
Conference publication: EUROPEAN HEART JOURNAL. 2021;42:1106
Long term outcome after a first myocardial infarction
Almosawi M; Ferrannini G; Buhlin K; Gustafsson A; Kjellstrom B; Klinge B; Nygren A; Nasman P; Svenungsson E; Ryden L; Norhammar A
Conference publication: EUROPEAN HEART JOURNAL. 2021;42:1120
Periodontitis and cardiovascular outcome - a prospective follow-up of the PAROKRANK cohort
Ferrannini G; Norhammar A; Almosawi M; Kjellstrom B; Buhlin K; De Faire U; Gustafsson A; Nygren LA; Nasman P; Lindahl B; Naslund U; Svenungsson E; Klinge B; Ryden L
Conference publication: EUROPEAN HEART JOURNAL. 2020;41:3353
Dulaglutide is cardioprotective with or without background metformin in patients with diabetes and established or high risk for coronary vascular disease. A subgroup analysis of the REWIND Trial
Ferrannini G; Gerstein HC; Colhoun HM; Dagenais GR; Diaz R; Dyal L; Lakshmanan M; Mellbin L; Probslfield J; Riddles MC; Shaw JE; Ryden L
Editorial comment: EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY. 2020;6(6):341-342
Cardiorenal protection of sodium-glucose cotransporter 2 inhibitors beyond diabetes: news from the European Society of Cardiology Congress 2020
Ferrannini G
Conference publication: DIABETOLOGIA. 2020;63(SUPPL 1):S282
Cardio protection with dulaglutide is not depending on baseline therapy with metformin: a subgroup analysis of the REWIND trial
Ferrannini G; Gerstein HC; Colhoun HM; Dagenais GR; Diaz R; Dyal L; Lakshmanan M; Mellbin L; Probstfield J; Riddle MC; Shaw JE; Ryden L
Conference publication: LUPUS. 2019;28:42
Dysglycaemic patients with antiphospholipid antibodies IgG: a neglected group at high cardiovascular risk?
Ferrannini G; Svenungsson E; Kjellstrom B; Elvin K; Grosso G; Nasman P; Ryden L; Norhammar A
Conference publication: LUPUS. 2019;28:39-40
Domain specific anti-β2GPI antibodies in patients with First Myocardial Infarction
Sippl N; Grosso G; Ferrannini G; de Faire U; Lindahl B; Nasman P; Norhammar A; Ryden L; Svenungsson E; Amara K
Review: CLINICAL SCIENCE. 2018;132(18):2003-2012
Sodium-glucose transporter 2 inhibition and cardiovascular events in patients with diabetes: information from clinical trials and observational real-world data
Ferrannini G; Ryden L
Conference publication: DIABETOLOGIA. 2014;57:S8
Energy balance following sodium-glucose co-transporter-2 (SGLT2) inhibition
Ferrannini G; Hach T; Crowe S; Ferrannini E
Conference publication: ENDOCRINE REVIEWS. 2014;35(3)
GH Deficiency in HIV-Infected Patients Compared to Hypopituitary Patients
Brigante G; Diazzi C; Ferrannini G; De Vincentis S; Guaraldi G; Ansaloni A; Simoni M; Rochira V
Show more

Employments

Postdoctoral Researcher, Department of Physiology and Pharmacology, Karolinska Institutet, 2024-2025
Postdoctoral Researcher, Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, 2024-2025

About me

Articles

All other publications

Employments

News from KI

Events from KI